PE20011294A1 - Composiciones farmaceuticas de agonistas/antagonistas de estrogeno y estatinas para tratar la osteoporosis y reducir el colesterol - Google Patents

Composiciones farmaceuticas de agonistas/antagonistas de estrogeno y estatinas para tratar la osteoporosis y reducir el colesterol

Info

Publication number
PE20011294A1
PE20011294A1 PE2001000079A PE2001000079A PE20011294A1 PE 20011294 A1 PE20011294 A1 PE 20011294A1 PE 2001000079 A PE2001000079 A PE 2001000079A PE 2001000079 A PE2001000079 A PE 2001000079A PE 20011294 A1 PE20011294 A1 PE 20011294A1
Authority
PE
Peru
Prior art keywords
phenyl
alkyl
reduce cholesterol
statines
antagonists
Prior art date
Application number
PE2001000079A
Other languages
English (en)
Inventor
Wesley Warren Day
David Duane Thompson
Andrew George Lee
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20011294A1 publication Critical patent/PE20011294A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA COMPOSICION QUE COMPRENDE: a)UN AGONISTA O ANTAGONISTA DE ESTROGENO DE FORMULA I DONDE A ES CH, NR; B, D Y E SON CH, N; Y ES FENILO, NAFTILO, CICLOALQUILO C3-C8, CICLOALQUENILO C3-C8, HETEROCICLO DE 5 MIEMBROS, ANILLO BICICLICO; Z1 ES (CH2)pW(CH2)q, O(CH2)pCR5R6, O(CH2)pW(CH2)q, ENTRE OTROS; G ES NR7R8, GRUPO a, AMINA BICICLICA; Z2 ES NH, O, S, CH2; W ES CH2, HC=CH, O, NR2, S(O)n, ENTRE OTROS; R ES H, ALQUILO C1-C6; R2 Y R3 SON H, ALQUILO C1-C4; R4 ES H, HALOGENO, ALQUILO C1-C6, ENTRE OTROS; R5 Y R6 SON ALQUILO C1-C8, FORMAN CARBOCICLO C3-C10; R7 Y R8 SON FENILO, ANILLO CARBOCICLO C3-C10, HETEROCICLO C3-C10, H; e Y n SON 0-2; m ES 1-3; p Y q SON 0-3; SIENDO UN COMPUESTO PREFERIDO (-)CIS-6-FENIL-5-[4-(2-PIRROLIDIN-1-ILETOXI)FENIL]-5,6,7,8-TETRAHIDRONAFTALEN-2-OL, TAMOXIFENO, RALOXIFENO, ENTRE OTROS; b)UNA ESTATINA TAL COMO SIMVASTATINA, PRAVASTATINA, CERIVASTATINA, MEVASTATINA, LOVASTATINA, ATORVASTATINA, ENTRE OTROS. LA COMPOSICION PUEDE SER UTIL PARA ESTIMULAR LA FORMACION DE HUESO; PREVENIR LA PERDIDA OSEA O REDUCIR COLESTEROL, TRATAR HIPERLIPIDEMIA
PE2001000079A 2000-01-26 2001-01-24 Composiciones farmaceuticas de agonistas/antagonistas de estrogeno y estatinas para tratar la osteoporosis y reducir el colesterol PE20011294A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18892300P 2000-01-26 2000-01-26
US20532700P 2000-04-21 2000-04-21

Publications (1)

Publication Number Publication Date
PE20011294A1 true PE20011294A1 (es) 2001-12-21

Family

ID=26884589

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000079A PE20011294A1 (es) 2000-01-26 2001-01-24 Composiciones farmaceuticas de agonistas/antagonistas de estrogeno y estatinas para tratar la osteoporosis y reducir el colesterol

Country Status (12)

Country Link
US (2) US6756401B2 (es)
EP (1) EP1123717A3 (es)
JP (1) JP2001206845A (es)
KR (1) KR20010083135A (es)
AU (1) AU780568B2 (es)
CA (1) CA2332214A1 (es)
CO (1) CO5251465A1 (es)
HU (1) HUP0100388A3 (es)
IL (1) IL140989A0 (es)
MY (1) MY133564A (es)
NZ (1) NZ523651A (es)
PE (1) PE20011294A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002003991A2 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for increasing nitric oxide synthase activity
AU2001271784A1 (en) * 2000-07-06 2002-01-21 Wyeth Therapy for prosthesis-related bone degeneration
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
JP2007531697A (ja) * 2003-07-11 2007-11-08 プロ−ファーマシューティカルズ，インコーポレイティド 疎水性薬剤のデリバリーのための組成物と方法
US20050053664A1 (en) * 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
EP1718146A2 (en) * 2004-02-13 2006-11-08 Pro-Pharmaceuticals, Inc. Compositions and methods used to treat acne and candida
JP2008500368A (ja) * 2004-05-27 2008-01-10 ミジェニックス コーポレイション 細胞保護のための２置換１７−イミノエストロゲン化合物
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
MX2007000762A (es) 2004-07-22 2007-04-02 Ptc Therapeutics Inc Tienopiridinas para tratamientode hepatitis c.
EP1773128A2 (en) * 2004-08-02 2007-04-18 Pro-Pharmaceuticals, Inc. Compositions and methods for the enhancement of chemotherapy with microbial cytotoxins
US7901710B2 (en) 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US8202546B2 (en) 2005-08-04 2012-06-19 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US7998500B2 (en) 2005-08-04 2011-08-16 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US8263137B2 (en) 2005-08-04 2012-09-11 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US8501690B2 (en) * 2010-04-30 2013-08-06 John G. Stark Use of selective estrogen receptor modulator for joint fusion and other repair or healing of connective tissue
PL2580210T3 (pl) 2010-06-10 2017-09-29 Seragon Pharmaceuticals, Inc. Modulatory receptora estrogenowego i ich zastosowania
EA029559B1 (ru) 2011-12-14 2018-04-30 Серагон Фармасьютикалс, Инк. Фторированные модуляторы рецепторов эстрогенов и их применение
IL310489A (en) 2015-10-01 2024-03-01 Olema Pharmaceuticals Inc Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs and preparations containing them for use in cancer treatment
WO2017100715A1 (en) 2015-12-09 2017-06-15 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective estrogen receptor downregulator compounds
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
EP3858835A1 (en) 2016-07-01 2021-08-04 G1 Therapeutics, Inc. Pyrimidine-based antiproliferative agents
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
BR112019013814A2 (pt) 2017-01-06 2020-01-21 G1 Therapeutics Inc método para tratamento de câncer ou de um tumor em um indivíduo, composição farmacêutica, combinação, e, kit.
AU2018291026B2 (en) 2017-06-29 2022-09-01 G1 Therapeutics, Inc. Morphic forms of GIT38 and methods of manufacture thereof
WO2020132561A1 (en) 2018-12-20 2020-06-25 C4 Therapeutics, Inc. Targeted protein degradation
WO2024030968A1 (en) 2022-08-03 2024-02-08 Brystol-Myers Squibb Company Compounds for modulating ret protein
WO2024097989A1 (en) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Ret-ldd protein degraders
WO2024097980A1 (en) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Ret-ldd protein inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612114B2 (es) * 1974-06-07 1981-03-18
GB2126576B (en) * 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
NO177005C (no) * 1988-01-20 1995-07-05 Bayer Ag Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
CA2040996A1 (en) * 1990-05-02 1991-11-03 Robert L. Albright Composition and method for controlling cholesterol
CA2356145A1 (en) * 1991-12-18 1993-06-24 Aktiebolaget Astra New combination of formoterol and budesonide
US5447922A (en) * 1994-08-24 1995-09-05 Bristol-Myers Squibb Company α-phosphonosulfinic squalene synthetase inhibitors
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
UA51676C2 (uk) 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
ZA979644B (en) 1996-10-28 1998-04-28 Novo Nordisk As Heterocyclic compounds, compositions and uses.
CA2274789A1 (en) 1996-12-13 1998-06-18 Zymogenetics, Inc. Compositions and methods for stimulating bone growth
US6080779A (en) 1996-12-13 2000-06-27 Osteoscreen, Inc. Compositions and methods for stimulating bone growth
US6653297B1 (en) 1997-07-03 2003-11-25 Medical College Of Hampton Roads Control of selective estrogen receptor modulators
CA2323448A1 (en) * 1998-03-13 1999-09-16 Merck & Co., Inc. Methods of inhibiting bone resorption

Also Published As

Publication number Publication date
US20030162807A1 (en) 2003-08-28
CO5251465A1 (es) 2003-02-28
KR20010083135A (ko) 2001-08-31
EP1123717A3 (en) 2003-10-15
HUP0100388A3 (en) 2006-02-28
AU780568B2 (en) 2005-04-07
EP1123717A2 (en) 2001-08-16
IL140989A0 (en) 2002-02-10
NZ523651A (en) 2004-06-25
AU1667501A (en) 2001-08-02
US20040259886A1 (en) 2004-12-23
HU0100388D0 (en) 2001-03-28
CA2332214A1 (en) 2001-07-26
HUP0100388A2 (hu) 2003-08-28
US6756401B2 (en) 2004-06-29
JP2001206845A (ja) 2001-07-31
MY133564A (en) 2007-11-30

Similar Documents

Publication Publication Date Title
PE20011294A1 (es) Composiciones farmaceuticas de agonistas/antagonistas de estrogeno y estatinas para tratar la osteoporosis y reducir el colesterol
PE20061297A1 (es) Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c
PE20011120A1 (es) Composiciones farmaceuticas de agonistas/antagonistas de estrogenos para reducir la morbilidad cardiovascular y el riesgo de mortalidad
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
HK1110868A1 (en) Heterocyclic compounds as ccr2b antagonists
TNSN06109A1 (fr) Derives [3.1.0] bicycliques servant d'inhibiteurs du transporteur de glycine
AR028952A1 (es) Antagonistas receptores de trombina
PE20090441A1 (es) DERIVADOS DE IMIDAZO[1,2-a]PIRIDIN-2-ILMETIL PIPERIDINA SUSTITUIDA
NO20020214L (no) Substituerte oksoazaheterocyklylforbindelser
PE20090048A1 (es) Derivados de glicina n-sustituidos: inhibidores de prolil hidroxilasa
UY27992A1 (es) Compuestos de piperidinil-imidazopiridina n-sustituidos como moduladores del receptor 5-ht
AR049276A1 (es) Compuestos carboxamidos opiodes y composiciones farmaceuticas que los contienen
EA200400467A1 (ru) Производные 3-азабицикло (3.1.0) гексана в качестве антагонистов опиоидного рецептора
DE69615674D1 (de) Cyclobutan-derivate als inhibitoren der squalen-synthase und der protein farnesyltransferase
AR018168A1 (es) Antagonista de nociceptina que comprende un derivado de amida, composicion farmaceutica y analgesica que lo incluye, uso de dicho derivado de amida yenvase comercial que comprende dicha composicion farmaceutica
ES2192264T3 (es) Sal mesilato trihidrato de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2(1h)-indol-2-ona (=ziprasidona), su preparacion y su uso como antagonista de la dopamina.
AR037736A1 (es) Derivados de pirimidina como moduladores o inhibidores de la actividad del factor de crecimiento insulinico tipo 1 (igf-1r)
PE20080209A1 (es) Derivados de glicina como inhibidores de prolil hidroxilasa
PA8581401A1 (es) Compuestos de imedazopiridina como agonistas del receptor 5-ht4
DE602005027230D1 (de) Cgrp-rezeptorantagonisten
EA200400466A1 (ru) Производные пиперазина с антагонистической активностью к рецептору ccr1
PE20001047A1 (es) METODO PARA TRATAR ATEROESCLEROSIS EMPLEANDO UN INHIBIDOR DE aP2 Y COMBINACION
AR063147A1 (es) Compuestos heterociclicos nitrogenados inhibidores de receptores de histamina h3, metodo de preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de trastornos del sistema nervioso central.
AR031526A1 (es) Nuevas fenilpiperazinas, composiciones farmaceuticas que las contienen, metodos para preparar los compuestos y las composiciones y uso de los compuestos en la preparacion de un medicamento.
YU53100A (sh) Derivati 2-ariletil-(piperidin-4-ilmetil)amina kao antagonisti muskarinskih receptora

Legal Events

Date Code Title Description
FC Refusal